Annual CFF
$187.07 M
+$187.76 M+27211.59%
31 December 2023
Summary:
EyePoint Pharmaceuticals annual cash flow from financing activities is currently $187.07 million, with the most recent change of +$187.76 million (+27211.59%) on 31 December 2023. During the last 3 years, it has risen by +$149.58 million (+398.96%). EYPT annual CFF is now -13.75% below its all-time high of $216.90 million, reached on 31 December 2021.EYPT Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$11.89 M
+$11.56 M+3514.89%
30 September 2024
Summary:
EyePoint Pharmaceuticals quarterly cash flow from financing activities is currently $11.89 million, with the most recent change of +$11.56 million (+3514.89%) on 30 September 2024. Over the past year, it has increased by +$1.53 million (+14.78%). EYPT quarterly CFF is now -94.56% below its all-time high of $218.49 million, reached on 31 December 2023.EYPT Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$230.82 M
+$1.53 M+0.67%
30 September 2024
Summary:
EyePoint Pharmaceuticals TTM cash flow from financing activities is currently $230.82 million, with the most recent change of +$1.53 million (+0.67%) on 30 September 2024. Over the past year, it has increased by +$262.30 million (+833.40%). EYPT TTM CFF is now at all-time high.EYPT TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EYPT Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +10000.0% | +14.8% | +833.4% |
| 3 y3 years | +399.0% | +10000.0% | +94.2% |
| 5 y5 years | +540.6% | +401.6% | +623.1% |
EYPT Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -13.8% | >+9999.0% | -94.6% | +132.4% | at high | +653.0% |
| 5 y | 5 years | -13.8% | >+9999.0% | -94.6% | +132.4% | at high | +653.0% |
| alltime | all time | -13.8% | >+9999.0% | -94.6% | +132.4% | at high | +653.0% |
EyePoint Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $11.89 M(+3514.9%) | $230.82 M(+0.7%) |
| June 2024 | - | $329.00 K(+186.1%) | $229.29 M(+19.2%) |
| Mar 2024 | - | $115.00 K(-99.9%) | $192.30 M(+2.8%) |
| Dec 2023 | $187.07 M(<-9900.0%) | $218.49 M(+2008.5%) | $187.07 M(-694.4%) |
| Sept 2023 | - | $10.36 M(-128.3%) | -$31.47 M(-24.6%) |
| June 2023 | - | -$36.66 M(+616.1%) | -$41.74 M(+678.6%) |
| Mar 2023 | - | -$5.12 M(+8725.9%) | -$5.36 M(+677.0%) |
| Dec 2022 | -$690.00 K(-100.3%) | -$58.00 K(-163.0%) | -$690.00 K(-100.6%) |
| Sept 2022 | - | $92.00 K(-133.3%) | $107.88 M(+0.1%) |
| June 2022 | - | -$276.00 K(-38.4%) | $107.79 M(+0.1%) |
| Mar 2022 | - | -$448.00 K(-100.4%) | $107.69 M(-50.4%) |
| Dec 2021 | $216.90 M(+478.5%) | $108.52 M(<-9900.0%) | $216.90 M(+82.5%) |
| Sept 2021 | - | -$2000.00(-99.5%) | $118.87 M(-4.0%) |
| June 2021 | - | -$381.00 K(-100.4%) | $123.77 M(-1.6%) |
| Mar 2021 | - | $108.77 M(+937.9%) | $125.81 M(+235.6%) |
| Dec 2020 | $37.49 M(+10.7%) | $10.48 M(+113.7%) | $37.49 M(+29.5%) |
| Sept 2020 | - | $4.90 M(+195.1%) | $28.96 M(+9.6%) |
| June 2020 | - | $1.66 M(-91.9%) | $26.42 M(-38.1%) |
| Mar 2020 | - | $20.45 M(+951.2%) | $42.68 M(+26.0%) |
| Dec 2019 | $33.86 M(+16.0%) | $1.95 M(-18.0%) | $33.86 M(+6.1%) |
| Sept 2019 | - | $2.37 M(-86.8%) | $31.92 M(-45.4%) |
| June 2019 | - | $17.91 M(+54.0%) | $58.41 M(-17.5%) |
| Mar 2019 | - | $11.63 M(-59.7%) | $70.76 M(-20.1%) |
| Dec 2018 | $29.20 M(-51.9%) | - | - |
| Sept 2018 | - | $28.86 M(-4.6%) | $88.57 M(+46.0%) |
| June 2018 | $60.67 M(+613.5%) | $30.27 M(+29.6%) | $60.67 M(+66.2%) |
| Mar 2018 | - | $23.36 M(+284.2%) | $36.50 M(+134.9%) |
| Dec 2017 | - | $6.08 M(+531.5%) | $15.54 M(+64.3%) |
| Sept 2017 | - | $963.00 K(-84.2%) | $9.46 M(+11.2%) |
| June 2017 | $8.50 M(-50.0%) | $6.10 M(+154.7%) | $8.50 M(+236.6%) |
| Mar 2017 | - | $2.40 M(>+9900.0%) | $2.53 M(-84.8%) |
| Dec 2016 | - | $0.00(-100.0%) | $16.66 M(-1.9%) |
| Sept 2016 | - | $9000.00(-92.6%) | $16.99 M(0.0%) |
| June 2016 | $16.99 M(+7129.8%) | $122.00 K(-99.3%) | $16.99 M(+0.7%) |
| Mar 2016 | - | $16.53 M(+4924.3%) | $16.87 M(+4890.5%) |
| Dec 2015 | - | $329.00 K(+3555.6%) | $338.00 K(+79.8%) |
| Sept 2015 | - | $9000.00(>+9900.0%) | $188.00 K(-20.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2015 | $235.00 K(-98.8%) | $0.00(0.0%) | $235.00 K(+6.3%) |
| Mar 2015 | - | $0.00(-100.0%) | $221.00 K(-97.1%) |
| Dec 2014 | - | $179.00 K(+219.6%) | $7.68 M(-15.8%) |
| Sept 2014 | - | $56.00 K(-500.0%) | $9.12 M(-52.1%) |
| June 2014 | $19.04 M(+307.9%) | -$14.00 K(-100.2%) | $19.04 M(-0.1%) |
| Mar 2014 | - | $7.46 M(+360.3%) | $19.06 M(+64.3%) |
| Dec 2013 | - | $1.62 M(-83.8%) | $11.60 M(+17.0%) |
| Sept 2013 | - | $9.98 M(>+9900.0%) | $9.91 M(+112.4%) |
| June 2013 | $4.67 M(+3995.6%) | $0.00(0.0%) | $4.67 M(0.0%) |
| Mar 2013 | - | $0.00(-100.0%) | $4.67 M(0.0%) |
| Dec 2012 | - | -$66.00 K(-101.4%) | $4.67 M(-1.4%) |
| Sept 2012 | - | $4.74 M(>+9900.0%) | $4.74 M(+4053.5%) |
| June 2012 | $114.00 K(-98.9%) | $0.00(0.0%) | $114.00 K(+22.6%) |
| Mar 2012 | - | $0.00(0.0%) | $93.00 K(-99.1%) |
| Dec 2011 | - | $0.00(-100.0%) | $10.17 M(0.0%) |
| Sept 2011 | - | $114.00 K(-642.9%) | $10.17 M(+1.1%) |
| June 2011 | $10.06 M(+1154.4%) | -$21.00 K(-100.2%) | $10.06 M(-0.2%) |
| Mar 2011 | - | $10.08 M(>+9900.0%) | $10.08 M(+3070.1%) |
| Dec 2010 | - | $0.00(0.0%) | $318.00 K(-60.3%) |
| Sept 2010 | - | $0.00(0.0%) | $802.00 K(0.0%) |
| June 2010 | $802.00 K(>+9900.0%) | $0.00(-100.0%) | $802.00 K(0.0%) |
| Mar 2010 | - | $318.00 K(-34.3%) | $802.00 K(+65.7%) |
| Dec 2009 | - | $484.00 K(>+9900.0%) | $484.00 K(>+9900.0%) |
| June 2009 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(-100.0%) |
| Mar 2009 | - | $0.00(0.0%) | -$2000.00(0.0%) |
| Dec 2008 | - | $0.00(0.0%) | -$2000.00(-100.8%) |
| Sept 2008 | - | $0.00(-100.0%) | $257.00 K(-98.6%) |
| June 2008 | $18.39 M(+81.5%) | -$2000.00(<-9900.0%) | $18.39 M(-0.0%) |
| Mar 2008 | - | $0.00(-100.0%) | $18.39 M(0.0%) |
| Dec 2007 | - | $259.00 K(-98.6%) | $18.39 M(+1.4%) |
| Sept 2007 | - | $18.13 M | $18.13 M |
| June 2007 | $10.13 M(-53.2%) | - | - |
| June 2006 | $21.65 M(+683.5%) | - | - |
| June 2005 | $2.76 M(-89.2%) | - | - |
| June 2004 | $25.68 M(+4383.1%) | - | - |
| June 2003 | $572.80 K(-59.5%) | - | - |
| June 2001 | $1.41 M | - | - |
FAQ
- What is EyePoint Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals annual CFF year-on-year change?
- What is EyePoint Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals quarterly CFF year-on-year change?
- What is EyePoint Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals TTM CFF year-on-year change?
What is EyePoint Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of EYPT is $187.07 M
What is the all time high annual CFF for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high annual cash flow from financing activities is $216.90 M
What is EyePoint Pharmaceuticals annual CFF year-on-year change?
Over the past year, EYPT annual cash flow from financing activities has changed by +$187.76 M (+27211.59%)
What is EyePoint Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of EYPT is $11.89 M
What is the all time high quarterly CFF for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high quarterly cash flow from financing activities is $218.49 M
What is EyePoint Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, EYPT quarterly cash flow from financing activities has changed by +$1.53 M (+14.78%)
What is EyePoint Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of EYPT is $230.82 M
What is the all time high TTM CFF for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high TTM cash flow from financing activities is $230.82 M
What is EyePoint Pharmaceuticals TTM CFF year-on-year change?
Over the past year, EYPT TTM cash flow from financing activities has changed by +$262.30 M (+833.40%)